Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863681 · ClinicalTrials.gov registry record · Phase 3
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 396
- Enrollment target
NCT00863681 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 396 participants.
The verdict
NCT00863681, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 396 participants
- Enrollment target
Study Summary
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
Interventions
- DRUG Riociguat (BAY63-2521)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2009-03-12 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00863681
The ClinicalTrials.gov registry entry for NCT00863681 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Riociguat (BAY63-2521) is the first listed.
NCT00863681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00863681 about?
NCT00863681 is a clinical study titled "BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension". Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
What is the current status of trial NCT00863681?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 396 participants. The study started on 2009-03-12. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT00863681?
The interventions under investigation include: Riociguat (BAY63-2521) (DRUG).
Who is sponsoring clinical trial NCT00863681?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.